HIV Lipodystrophy Syndrome
4
0
0
2
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
5 treatments under study, led by Nucleoside Reverse Transcriptase Inhibitors
Research Leaders
7 sponsors active, led by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
50.0%
2 terminated out of 4 trials
50.0%
-36.6% vs benchmark
50%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Body Composition and Adipose Tissue in HIV
Energy Expenditure of People Living With HIV/AIDS
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
Research Network
Common Treatments
- Nucleoside Reverse Transcriptase Inhibitors1
- Protease Inhibitors1
- Nonnucleoside Reverse Transcriptase Inhibitors1
- Use Of Lipidlowering Drugs1
- Tesamorelin1
Active Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1
- National Institute of Allergy and Infectious Diseases (NIAID)1
- University of Sao Paulo General Hospital1
- Columbia University1
Top Investigators
Service des Maladies Infectieuses Hopital Pitie-Salpetriere Paris
University of Alabama at Birmingham
University of Florida
Inserm U720
Columbia University
Related Conditions
- Hiv Infections2
- Hivaids1
- Osteoporosis1
- Body Composition1
- Osteopenia1